Logo image of ELTX

ELICIO THERAPEUTICS INC (ELTX) Stock Fundamental Analysis

NASDAQ:ELTX - Nasdaq - US28657F1030 - Common Stock - Currency: USD

5.61  -0.23 (-3.94%)

Fundamental Rating

0

Overall ELTX gets a fundamental rating of 0 out of 10. We evaluated ELTX against 561 industry peers in the Biotechnology industry. ELTX may be in some trouble as it scores bad on both profitability and health. ELTX is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year ELTX has reported negative net income.
ELTX had a negative operating cash flow in the past year.
ELTX had negative earnings in each of the past 5 years.
ELTX had a negative operating cash flow in each of the past 5 years.
ELTX Yearly Net Income VS EBIT VS OCF VS FCFELTX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M -80M

1.2 Ratios

The Return On Assets of ELTX (-245.49%) is worse than 92.51% of its industry peers.
Industry RankSector Rank
ROA -245.49%
ROE N/A
ROIC N/A
ROA(3y)-86.57%
ROA(5y)-154.17%
ROE(3y)-155.03%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ELTX Yearly ROA, ROE, ROICELTX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 0 200 -200 400

1.3 Margins

ELTX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ELTX Yearly Profit, Operating, Gross MarginsELTX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 0 -500 -1K -1.5K -2K -2.5K

More info and screens

0

2. Health

2.1 Basic Checks

ELTX does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for ELTX has been increased compared to 1 year ago.
ELTX has more shares outstanding than it did 5 years ago.
ELTX has a worse debt/assets ratio than last year.
ELTX Yearly Shares OutstandingELTX Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M
ELTX Yearly Total Debt VS Total AssetsELTX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

2.2 Solvency

ELTX has an Altman-Z score of -19.85. This is a bad value and indicates that ELTX is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of ELTX (-19.85) is worse than 86.45% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -19.85
ROIC/WACCN/A
WACC9.85%
ELTX Yearly LT Debt VS Equity VS FCFELTX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 50M -50M

2.3 Liquidity

A Current Ratio of 0.88 indicates that ELTX may have some problems paying its short term obligations.
With a Current ratio value of 0.88, ELTX is not doing good in the industry: 90.20% of the companies in the same industry are doing better.
ELTX has a Quick Ratio of 0.88. This is a bad value and indicates that ELTX is not financially healthy enough and could expect problems in meeting its short term obligations.
With a Quick ratio value of 0.88, ELTX is not doing good in the industry: 89.48% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 0.88
Quick Ratio 0.88
ELTX Yearly Current Assets VS Current LiabilitesELTX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

More info and screens

1

3. Growth

3.1 Past

EPS 1Y (TTM)N/A
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%24.35%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 14.00% on average over the next years. This is quite good.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y39.45%
EPS Next 2Y23.3%
EPS Next 3Y18.86%
EPS Next 5Y14%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ELTX Yearly Revenue VS EstimatesELTX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2029 2030 2031 2032 5M 10M 15M 20M 25M
ELTX Yearly EPS VS EstimatesELTX Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 -10 -20 -30 -40 -50

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ELTX. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ELTX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ELTX Price Earnings VS Forward Price EarningsELTX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ELTX Per share dataELTX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share -1 -2 -3

4.3 Compensation for Growth

A more expensive valuation may be justified as ELTX's earnings are expected to grow with 18.86% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y23.3%
EPS Next 3Y18.86%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ELTX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ELICIO THERAPEUTICS INC

NASDAQ:ELTX (5/20/2025, 2:46:26 PM)

5.61

-0.23 (-3.94%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-13 2025-05-13/amc
Earnings (Next)08-11 2025-08-11
Inst Owners9.42%
Inst Owner Change221.73%
Ins Owners2.17%
Ins Owner Change19.46%
Market Cap89.48M
Analysts80
Price Target12.24 (118.18%)
Short Float %1.3%
Short Ratio2.98
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)15.6%
Min EPS beat(2)-3.44%
Max EPS beat(2)34.64%
EPS beat(4)1
Avg EPS beat(4)-35.75%
Min EPS beat(4)-118.56%
Max EPS beat(4)34.64%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)9.09%
PT rev (3m)26.32%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)-3.79%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-3.92
EYN/A
EPS(NY)-2.01
Fwd EYN/A
FCF(TTM)-2.27
FCFYN/A
OCF(TTM)-2.27
OCFYN/A
SpS0
BVpS-0.1
TBVpS-0.1
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -245.49%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-86.57%
ROA(5y)-154.17%
ROE(3y)-155.03%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 11.66%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.88
Quick Ratio 0.88
Altman-Z -19.85
F-Score4
WACC9.85%
ROIC/WACCN/A
Cap/Depr(3y)142.62%
Cap/Depr(5y)189.57%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)N/A
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%24.35%
EPS Next Y39.45%
EPS Next 2Y23.3%
EPS Next 3Y18.86%
EPS Next 5Y14%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-60.62%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-48.56%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y34.39%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y34.44%
OCF growth 3YN/A
OCF growth 5YN/A